_id
6911b9c6ccc777a4e85d6131
Ticker
GBIM
Name
GlobeImmune Inc
Exchange
PINK
Address
1450 Infinite Drive, Louisville, CO, United States, 80027
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.globeimmune.com
Description
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.
Last Close
0.0001
Volume
7000
Current Price
0.0001
Change
0
Last Updated
2026-01-03T12:23:00.011Z
Image
data:image/webp;base64,UklGRkgBAABXRUJQVlA4IDwBAADQBwCdASpAAEAAPtFYokwoJSMiMBn5AQAaCWkA1UMudgBpAmbigUSZaJTiKpCeJWJ+yT8XaQmu33WzvmEGE3fxsIE2MmAgAAD+9BhpbWvZ7OxAJL4oRzC+BFjeMWleBHeYHj6qmZq/RY9DUuvIWlQ5Q+l75ghH/COZ3KUE063Xn64ImT6gmuIJnUbXB8KUwkx9nRjYeUyGxB/i0P/lSx6C0xU0Vtvv7WtoSwPEl/nMwrTQug6Qy4Qm+3bs62ltF8acishd0AhH8A7T2/NubLhLXIheO2v6SpwIacnp3Io5QOdeepQy7ynatSGInjh7s+S1OIZPJ7rUJc+1cjyyU7F85fkzzgQafJghlU60XIq01ZWycBok2bsc/Qxn4NLyw0vRzGK2PpDuWOX22J7Vhbwj6fOdNiXStn5nFgAA
Ipo Date
2014-07-02T00:00:00.000Z
Market Cap
575
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2016-03-31
Revenue
942750
Cost Of Revenue
514725
Gross Profit
428025
Operating Expenses
1804958
Operating Income
-862208
Interest Expense
0
Pretax Income
-862208
Net Income
-862208
Eps
-0.14990818165601277
Dividends Per Share
0
Shares Outstanding
5751574
Income Tax Expense
0
EBITDA
-843123
Operating Margin
-91.45669583664811
Total Other Income Expense Net
0
Cash
8693718
Short Term Investments
0
Receivables
0
Inventories
0
Total Current Assets
9449676
Property Plant Equipment
190636
Total Assets
9770957
Payables
407672
Short Term Debt
0
Long Term Debt
0
Total Liabilities
7620793
Equity
2150164
Bs_currency_symbol
USD
Depreciation
19085
Change In Working Capital
-387853
Cash From Operations
-1207004
Capital Expenditures
0
Cash From Investing
0
Cash From Financing
0
Net Change In Cash
-1207004
Cf_currency_symbol
USD
PE
-
PB
0.000267494665523188
ROE
-40.09963891126445
ROA
-8.82419193943848
FCF
-1207004
Fcf Percent
-1.2803012463537524
Piotroski FScore
0
Health Score
15
Deep Value Investing Score
5
Defensive Investing Score
5.5
Dividend Investing Score
1.5
Economic Moat Investing Score
3.8
Garp Investing Score
1
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
6.5
Quality Investing Score
1
Value Investing Score
3.5
Quarters > 0 > quarter
2016-03-31
Quarters > 0 > income Statement > revenue
942750
Quarters > 0 > income Statement > cost Of Revenue
514725
Quarters > 0 > income Statement > gross Profit
428025
Quarters > 0 > income Statement > operating Expenses
1804958
Quarters > 0 > income Statement > operating Income
-862208
Quarters > 0 > income Statement > interest Expense
0
Quarters > 0 > income Statement > pretax Income
-862208
Quarters > 0 > income Statement > net Income
-862208
Quarters > 0 > income Statement > eps
-0.14990818165601277
Quarters > 0 > income Statement > dividends Per Share
0
Quarters > 0 > income Statement > shares Outstanding
5751574
Quarters > 0 > income Statement > income Tax Expense
0
Quarters > 0 > income Statement > EBITDA
-843123
Quarters > 0 > income Statement > operating Margin
-91.45669583664811
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
8693718
Quarters > 0 > balance Sheet > short Term Investments
0
Quarters > 0 > balance Sheet > receivables
0
Quarters > 0 > balance Sheet > inventories
0
Quarters > 0 > balance Sheet > total Current Assets
9449676
Quarters > 0 > balance Sheet > property Plant Equipment
190636
Quarters > 0 > balance Sheet > total Assets
9770957
Quarters > 0 > balance Sheet > payables
407672
Quarters > 0 > balance Sheet > short Term Debt
0
Quarters > 0 > balance Sheet > long Term Debt
0
Quarters > 0 > balance Sheet > total Liabilities
7620793
Quarters > 0 > balance Sheet > equity
2150164
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-862208
Quarters > 0 > cash Flow > depreciation
19085
Quarters > 0 > cash Flow > change In Working Capital
-387853
Quarters > 0 > cash Flow > cash From Operations
-1207004
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
0
Quarters > 0 > cash Flow > cash From Financing
0
Quarters > 0 > cash Flow > net Change In Cash
-1207004
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.14990818165601277
Quarters > 0 > ratios > PB
0.000267494665523188
Quarters > 0 > ratios > ROE
-40.09963891126445
Quarters > 0 > ratios > ROA
-8.82419193943848
Quarters > 0 > ratios > FCF
-1207004
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-1.2803012463537524
Quarters > 0 > health Score
15
Quarters > 1 > quarter
2015-12-31
Quarters > 1 > income Statement > revenue
1047914
Quarters > 1 > income Statement > cost Of Revenue
232893
Quarters > 1 > income Statement > gross Profit
815021
Quarters > 1 > income Statement > operating Expenses
1842946
Quarters > 1 > income Statement > operating Income
-795032
Quarters > 1 > income Statement > interest Expense
0
Quarters > 1 > income Statement > pretax Income
-795032
Quarters > 1 > income Statement > net Income
-795032
Quarters > 1 > income Statement > eps
-0.1382285962068818
Quarters > 1 > income Statement > dividends Per Share
0
Quarters > 1 > income Statement > shares Outstanding
5751574
Quarters > 1 > income Statement > income Tax Expense
100000
Quarters > 1 > income Statement > EBITDA
-775479
Quarters > 1 > income Statement > operating Margin
-75.86805787497829
Quarters > 1 > income Statement > total Other Income Expense Net
100000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
9900722
Quarters > 1 > balance Sheet > short Term Investments
0
Quarters > 1 > balance Sheet > receivables
0
Quarters > 1 > balance Sheet > inventories
0
Quarters > 1 > balance Sheet > total Current Assets
11090775
Quarters > 1 > balance Sheet > property Plant Equipment
209721
Quarters > 1 > balance Sheet > total Assets
11506141
Quarters > 1 > balance Sheet > payables
234070
Quarters > 1 > balance Sheet > short Term Debt
0
Quarters > 1 > balance Sheet > long Term Debt
0
Quarters > 1 > balance Sheet > total Liabilities
8517741
Quarters > 1 > balance Sheet > equity
2988400
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-795032
Quarters > 1 > cash Flow > depreciation
19553
Quarters > 1 > cash Flow > change In Working Capital
-649682
Quarters > 1 > cash Flow > cash From Operations
-1408496
Quarters > 1 > cash Flow > capital Expenditures
307612.89
Quarters > 1 > cash Flow > cash From Investing
13671
Quarters > 1 > cash Flow > cash From Financing
0
Quarters > 1 > cash Flow > net Change In Cash
-1394825
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.1382285962068818
Quarters > 1 > ratios > PB
0.00019246332485611028
Quarters > 1 > ratios > ROE
-26.603935216169187
Quarters > 1 > ratios > ROA
-6.9096319956447605
Quarters > 1 > ratios > FCF
-1716108.8900000001
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-1.6376428695484555
Quarters > 1 > health Score
19
Quarters > 2 > quarter
2015-09-30
Quarters > 2 > income Statement > revenue
2944947
Quarters > 2 > income Statement > cost Of Revenue
579822
Quarters > 2 > income Statement > gross Profit
2365125
Quarters > 2 > income Statement > operating Expenses
2051345
Quarters > 2 > income Statement > operating Income
893602
Quarters > 2 > income Statement > interest Expense
0
Quarters > 2 > income Statement > pretax Income
893602
Quarters > 2 > income Statement > net Income
893602
Quarters > 2 > income Statement > eps
0.12864222153217783
Quarters > 2 > income Statement > dividends Per Share
0
Quarters > 2 > income Statement > shares Outstanding
6946413
Quarters > 2 > income Statement > income Tax Expense
-100000
Quarters > 2 > income Statement > EBITDA
914135
Quarters > 2 > income Statement > operating Margin
30.343568152499856
Quarters > 2 > income Statement > total Other Income Expense Net
-100000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
11295547
Quarters > 2 > balance Sheet > short Term Investments
0
Quarters > 2 > balance Sheet > receivables
0
Quarters > 2 > balance Sheet > inventories
0
Quarters > 2 > balance Sheet > total Current Assets
12881988
Quarters > 2 > balance Sheet > property Plant Equipment
230271
Quarters > 2 > balance Sheet > total Assets
13212259
Quarters > 2 > balance Sheet > payables
285593
Quarters > 2 > balance Sheet > short Term Debt
0
Quarters > 2 > balance Sheet > long Term Debt
0
Quarters > 2 > balance Sheet > total Liabilities
9458166
Quarters > 2 > balance Sheet > equity
3754093
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
893602
Quarters > 2 > cash Flow > depreciation
20533
Quarters > 2 > cash Flow > change In Working Capital
-2100888
Quarters > 2 > cash Flow > cash From Operations
-1308177
Quarters > 2 > cash Flow > capital Expenditures
1594
Quarters > 2 > cash Flow > cash From Investing
238437
Quarters > 2 > cash Flow > cash From Financing
0
Quarters > 2 > cash Flow > net Change In Cash
-1069740
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
0.12864222153217783
Quarters > 2 > ratios > PB
0.0001850357196798268
Quarters > 2 > ratios > ROE
23.803406042418235
Quarters > 2 > ratios > ROA
6.763430841009097
Quarters > 2 > ratios > FCF
-1309771
Quarters > 2 > ratios > Piotroski FScore
2
Quarters > 2 > ratios > fcf Percent
-0.4447519768607041
Quarters > 2 > health Score
56
Quarters > 3 > quarter
2015-06-30
Quarters > 3 > income Statement > revenue
1277047
Quarters > 3 > income Statement > cost Of Revenue
752530
Quarters > 3 > income Statement > gross Profit
524517
Quarters > 3 > income Statement > operating Expenses
2581994
Quarters > 3 > income Statement > operating Income
-1304947
Quarters > 3 > income Statement > interest Expense
0
Quarters > 3 > income Statement > pretax Income
-1304947
Quarters > 3 > income Statement > net Income
-1304947
Quarters > 3 > income Statement > eps
-0.22688519699129317
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
5751574
Quarters > 3 > income Statement > income Tax Expense
0
Quarters > 3 > income Statement > EBITDA
-1236728
Quarters > 3 > income Statement > operating Margin
-102.18472773515774
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
12365287
Quarters > 3 > balance Sheet > short Term Investments
0
Quarters > 3 > balance Sheet > receivables
0
Quarters > 3 > balance Sheet > inventories
0
Quarters > 3 > balance Sheet > total Current Assets
13092461
Quarters > 3 > balance Sheet > property Plant Equipment
342667
Quarters > 3 > balance Sheet > total Assets
13535128
Quarters > 3 > balance Sheet > payables
703929
Quarters > 3 > balance Sheet > short Term Debt
0
Quarters > 3 > balance Sheet > long Term Debt
0
Quarters > 3 > balance Sheet > total Liabilities
10699787
Quarters > 3 > balance Sheet > equity
2835341
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-1304947
Quarters > 3 > cash Flow > depreciation
68219
Quarters > 3 > cash Flow > change In Working Capital
-788967
Quarters > 3 > cash Flow > cash From Operations
-1981217
Quarters > 3 > cash Flow > capital Expenditures
10211
Quarters > 3 > cash Flow > cash From Investing
-10211
Quarters > 3 > cash Flow > cash From Financing
0
Quarters > 3 > cash Flow > net Change In Cash
-1991428
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.22688519699129317
Quarters > 3 > ratios > PB
0.0002028529901694364
Quarters > 3 > ratios > ROE
-46.02434063486543
Quarters > 3 > ratios > ROA
-9.641186991360556
Quarters > 3 > ratios > FCF
-1991428
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-1.559400711171946
Quarters > 3 > health Score
15
Annuals > 0 > quarter
2022-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
-
Annuals > 0 > income Statement > operating Income
-
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-
Annuals > 0 > income Statement > net Income
-
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
-
Annuals > 0 > balance Sheet > cash
-
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
-
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
-
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
-
Annuals > 0 > balance Sheet > equity
-
Annuals > 0 > balance Sheet > currency_symbol
-
Annuals > 0 > cash Flow > net Income
-
Annuals > 0 > cash Flow > depreciation
228485
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
-
Annuals > 0 > cash Flow > capital Expenditures
-
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
-
Annuals > 0 > cash Flow > currency_symbol
-
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
-
Annuals > 0 > ratios > ROA
-
Annuals > 0 > ratios > FCF
-
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
45
Annuals > 1 > quarter
2021-12-31
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
-
Annuals > 1 > income Statement > operating Income
-
Annuals > 1 > income Statement > interest Expense
-
Annuals > 1 > income Statement > pretax Income
-
Annuals > 1 > income Statement > net Income
-
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
-
Annuals > 1 > balance Sheet > cash
-
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
-
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
-
Annuals > 1 > balance Sheet > payables
-
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
-
Annuals > 1 > balance Sheet > equity
-
Annuals > 1 > balance Sheet > currency_symbol
-
Annuals > 1 > cash Flow > net Income
-
Annuals > 1 > cash Flow > depreciation
236558
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
-
Annuals > 1 > cash Flow > capital Expenditures
-
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
-
Annuals > 1 > cash Flow > currency_symbol
-
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
-
Annuals > 1 > ratios > ROA
-
Annuals > 1 > ratios > FCF
-
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
45
Annuals > 2 > quarter
2020-12-31
Annuals > 2 > income Statement > revenue
-
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
-
Annuals > 2 > income Statement > operating Income
-
Annuals > 2 > income Statement > interest Expense
-
Annuals > 2 > income Statement > pretax Income
-
Annuals > 2 > income Statement > net Income
-
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
-
Annuals > 2 > balance Sheet > cash
-
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
-
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
-
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
-
Annuals > 2 > balance Sheet > equity
-
Annuals > 2 > balance Sheet > currency_symbol
-
Annuals > 2 > cash Flow > net Income
-
Annuals > 2 > cash Flow > depreciation
206297
Annuals > 2 > cash Flow > change In Working Capital
-
Annuals > 2 > cash Flow > cash From Operations
-
Annuals > 2 > cash Flow > capital Expenditures
-
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
-
Annuals > 2 > cash Flow > currency_symbol
-
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
-
Annuals > 2 > ratios > ROA
-
Annuals > 2 > ratios > FCF
-
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
45
Annuals > 3 > quarter
2019-12-31
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
-
Annuals > 3 > income Statement > operating Income
-
Annuals > 3 > income Statement > interest Expense
-
Annuals > 3 > income Statement > pretax Income
-
Annuals > 3 > income Statement > net Income
-
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
-
Annuals > 3 > balance Sheet > cash
-
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
-
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
-
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
-
Annuals > 3 > balance Sheet > equity
-
Annuals > 3 > balance Sheet > currency_symbol
-
Annuals > 3 > cash Flow > net Income
-
Annuals > 3 > cash Flow > depreciation
171860
Annuals > 3 > cash Flow > change In Working Capital
-
Annuals > 3 > cash Flow > cash From Operations
-
Annuals > 3 > cash Flow > capital Expenditures
-
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
-
Annuals > 3 > cash Flow > currency_symbol
-
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-
Annuals > 3 > ratios > ROA
-
Annuals > 3 > ratios > FCF
-
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
45
Valuation > metrics > PE
-0.14990818165601277
Valuation > metrics > PB
0.000267494665523188
Valuation > final Score
70
Valuation > verdict
100.0% Undervalued
Profitability > metrics > ROE
-40.09963891126445
Profitability > metrics > ROA
-9.124207009848803
Profitability > metrics > Net Margin
-0.914566958366481
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
3.5442845289940674
Risk > metrics > Interest Coverage
-45.17725962798009
Risk > final Score
-175
Risk > verdict
High
Liquidity > metrics > Current Ratio
23.179605172785966
Liquidity > metrics > Quick Ratio
23.179605172785966
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
90
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
91
Prev Profitabilities > 2
0
Prev Risks > 0
-145
Prev Risks > 1
58
Prev Risks > 2
-71
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-22T21:11:03.391Z
Earnings History > 0 > period
2016-03-31
Earnings History > 0 > report Date
2016-05-12
Earnings History > 0 > date
2016-03-31
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
USD
Earnings History > 0 > eps Actual
-0.15
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2015-12-31
Earnings History > 1 > report Date
2016-03-16
Earnings History > 1 > date
2015-12-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
USD
Earnings History > 1 > eps Actual
-0.14
Earnings History > 1 > eps Estimate
-
Earnings History > 1 > eps Difference
0
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2015-09-30
Earnings History > 2 > report Date
2015-11-13
Earnings History > 2 > date
2015-09-30
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
0.13
Earnings History > 2 > eps Estimate
-
Earnings History > 2 > eps Difference
0
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2015-06-30
Earnings History > 3 > report Date
2015-08-14
Earnings History > 3 > date
2015-06-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.23
Earnings History > 3 > eps Estimate
-
Earnings History > 3 > eps Difference
0
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2015-03-31
Earnings History > 4 > report Date
2015-05-14
Earnings History > 4 > date
2015-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.27
Earnings History > 4 > eps Estimate
-
Earnings History > 4 > eps Difference
0
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2014-12-31
Earnings History > 5 > report Date
2015-03-31
Earnings History > 5 > date
2014-12-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.2713
Earnings History > 5 > eps Estimate
-
Earnings History > 5 > eps Difference
0
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2014-09-30
Earnings History > 6 > report Date
2014-12-31
Earnings History > 6 > date
2014-09-30
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.3018
Earnings History > 6 > eps Estimate
-
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
-
Earnings History > 7 > period
2014-06-30
Earnings History > 7 > report Date
2014-09-30
Earnings History > 7 > date
2014-06-30
Earnings History > 7 > before After Market
-
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-1.1837
Earnings History > 7 > eps Estimate
0
Earnings History > 7 > eps Difference
-1.1837
Earnings History > 7 > surprise Percent
-
Earnings History > 8 > period
2014-03-31
Earnings History > 8 > report Date
2014-06-30
Earnings History > 8 > date
2014-03-31
Earnings History > 8 > before After Market
-
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-93.319
Earnings History > 8 > eps Estimate
0
Earnings History > 8 > eps Difference
-93.319
Earnings History > 8 > surprise Percent
-
Earnings History > 9 > period
2013-12-31
Earnings History > 9 > report Date
2014-03-31
Earnings History > 9 > date
2013-12-31
Earnings History > 9 > before After Market
-
Earnings History > 9 > currency
USD
Earnings History > 9 > eps Actual
-63.1122
Earnings History > 9 > eps Estimate
0
Earnings History > 9 > eps Difference
-63.1122
Earnings History > 9 > surprise Percent
-
Earnings History > 10 > period
2013-09-30
Earnings History > 10 > report Date
2013-12-31
Earnings History > 10 > date
2013-09-30
Earnings History > 10 > before After Market
-
Earnings History > 10 > currency
USD
Earnings History > 10 > eps Actual
80.0916
Earnings History > 10 > eps Estimate
0
Earnings History > 10 > eps Difference
80.0916
Earnings History > 10 > surprise Percent
-
Earnings History > 11 > period
2013-06-30
Earnings History > 11 > report Date
2013-09-30
Earnings History > 11 > date
2013-06-30
Earnings History > 11 > before After Market
-
Earnings History > 11 > currency
USD
Earnings History > 11 > eps Actual
-42.49
Earnings History > 11 > eps Estimate
0
Earnings History > 11 > eps Difference
-42.49
Earnings History > 11 > surprise Percent
-
Earnings History > 12 > period
2013-03-31
Earnings History > 12 > report Date
2013-06-30
Earnings History > 12 > date
2013-03-31
Earnings History > 12 > before After Market
-
Earnings History > 12 > currency
USD
Earnings History > 12 > eps Actual
-23.1589
Earnings History > 12 > eps Estimate
0
Earnings History > 12 > eps Difference
-23.1589
Earnings History > 12 > surprise Percent
-
Earnings History > 13 > period
2012-12-31
Earnings History > 13 > report Date
2013-03-31
Earnings History > 13 > date
2012-12-31
Earnings History > 13 > before After Market
-
Earnings History > 13 > currency
USD
Earnings History > 13 > eps Actual
-51.6375
Earnings History > 13 > eps Estimate
0
Earnings History > 13 > eps Difference
-51.6375
Earnings History > 13 > surprise Percent
-
Earnings History > 14 > period
2012-03-31
Earnings History > 14 > report Date
2012-06-30
Earnings History > 14 > date
2012-03-31
Earnings History > 14 > before After Market
-
Earnings History > 14 > currency
USD
Earnings History > 14 > eps Actual
-46.1475
Earnings History > 14 > eps Estimate
0
Earnings History > 14 > eps Difference
-46.1475
Earnings History > 14 > surprise Percent
-
Earnings History > 15 > period
2011-12-31
Earnings History > 15 > report Date
2012-03-31
Earnings History > 15 > date
2011-12-31
Earnings History > 15 > before After Market
-
Earnings History > 15 > currency
USD
Earnings History > 15 > eps Actual
-60.0403
Earnings History > 15 > eps Estimate
0
Earnings History > 15 > eps Difference
-60.0403
Earnings History > 15 > surprise Percent
-
Earnings History > 16 > period
2011-09-30
Earnings History > 16 > report Date
2011-12-31
Earnings History > 16 > date
2011-09-30
Earnings History > 16 > before After Market
-
Earnings History > 16 > currency
USD
Earnings History > 16 > eps Actual
-73.5629
Earnings History > 16 > eps Estimate
0
Earnings History > 16 > eps Difference
-73.5629
Earnings History > 16 > surprise Percent
-
Earnings History > 17 > period
2011-06-30
Earnings History > 17 > report Date
2011-09-30
Earnings History > 17 > date
2011-06-30
Earnings History > 17 > before After Market
-
Earnings History > 17 > currency
USD
Earnings History > 17 > eps Actual
-73.5629
Earnings History > 17 > eps Estimate
0
Earnings History > 17 > eps Difference
-73.5629
Earnings History > 17 > surprise Percent
-
Earnings History > 18 > period
2011-03-31
Earnings History > 18 > report Date
2011-06-30
Earnings History > 18 > date
2011-03-31
Earnings History > 18 > before After Market
-
Earnings History > 18 > currency
USD
Earnings History > 18 > eps Actual
-68.3147
Earnings History > 18 > eps Estimate
0
Earnings History > 18 > eps Difference
-68.3147
Earnings History > 18 > surprise Percent
-
Earnings History > 19 > period
2010-12-31
Earnings History > 19 > report Date
2011-03-31
Earnings History > 19 > date
2010-12-31
Earnings History > 19 > before After Market
-
Earnings History > 19 > currency
USD
Earnings History > 19 > eps Actual
-69.5536
Earnings History > 19 > eps Estimate
0
Earnings History > 19 > eps Difference
-69.5536
Earnings History > 19 > surprise Percent
-
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of NantCell, Inc.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAllstate Corp Purchases New Holdings in Bristol Myers Squibb Company $BMY Defense World
Read more →(Last Updated 2016-03-31)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of GlobeImmune Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2016-03-31
EPS Actual
-0.15
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2016-03-31)
(Last Updated 2016-03-31)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2016-03-31)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2016-03-31)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.